EWG Elevate Inc. Invests $480,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

EWG Elevate Inc. purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 28,000 shares of the biotechnology company's stock, valued at approximately $480,000.

Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC bought a new position in ADMA Biologics during the 2nd quarter worth $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics during the 3rd quarter worth about $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics during the 3rd quarter worth about $31,000. GAMMA Investing LLC lifted its holdings in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the period. Finally, National Bank of Canada FI acquired a new position in ADMA Biologics during the 3rd quarter worth about $35,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 11.2 %

ADMA traded down $2.07 on Monday, hitting $16.49. The company had a trading volume of 4,030,063 shares, compared to its average volume of 2,485,737. The stock has a fifty day simple moving average of $19.39 and a 200-day simple moving average of $17.15. ADMA Biologics, Inc. has a 52-week low of $4.82 and a 52-week high of $23.64. The firm has a market capitalization of $3.90 billion, a P/E ratio of 58.89 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm earned $0.01 earnings per share. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.